首页> 外文期刊>BMC Cancer >High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers
【24h】

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers

机译:EGFR高蛋白表达和9外显子PIK3CA突变是三阴性乳腺癌的独立预后因素

获取原文
           

摘要

Background Triple negative breast cancers (TNBC) are a more aggressive subset of breast cancer. A better understanding of its biology could allow the rational development of targeted therapies. Methods We extensively analyzed the EGFR/PI3K/PTEN axis in a large, homogeneous population of TNBC to help defining the putative role of anti-EGFR and -PI3K targeted therapies in this setting. EGFR gene amplification, EGFR protein expression, PIK3CA and PTEN gene alterations (two members of EGFR downstream pathways) and their clinicopathological and prognostic implications were analyzed in 204 TNBC samples from European patients. Results EGFR amplification was detected in 18 of the 204 TNBC specimens (8.9?%) and was significantly associated with higher EGFR protein levels. Fourteen PIK3CA mutations were identified in exon 9 (6.7?%), and 17 in exon 20 (8.3?%). PIK3CA mutations, especially in exon 9, were significantly associated with grade I-II tumors. PTEN deletions were detected in 43 samples (21.50?%) and were significantly associated with grade III tumors ( p Conclusions High EGFR protein expression and exon 9 PIK3CA activating mutations are independent prognostic factors in TNBC. The efficacy of anti-PI3K targeted therapies needs to be evaluated in this setting.
机译:背景技术三阴性乳腺癌(TNBC)是乳腺癌中更具侵略性的子集。对它的生物学更好的理解可以使靶向疗法的合理发展。方法我们广泛分析了大量同质TNBC群体中的EGFR / PI3K / PTEN轴,以帮助确定在这种情况下抗EGFR和-PI3K靶向疗法的假定作用。在欧洲患者的204份TNBC样本中分析了EGFR基因扩增,EGFR蛋白表达,PIK3CA和PTEN基因改变(EGFR下游通路的两个成员)及其临床病理和预后影响。结果204例TNBC标本中有18份检测到EGFR扩增(8.9%),并与较高的EGFR蛋白水平显着相关。在第9外显子(6.7%)中鉴定出14个PIK3CA突变,在第20外显子(8.3 %%)中鉴定出17个。 PIK3CA突变,特别是第9外显子,与I-II级肿瘤显着相关。在43个样本中检测到PTEN缺失(21.50%),并与III级肿瘤显着相关(p结论EGFR蛋白高表达和9外显子PIK3CA激活突变是TNBC的独立预后因素。抗PI3K靶向治疗的疗效需要在此设置中进行评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号